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SUMMARY
To determine whether the antihypertensive effectiveness
of lercanidipine was independent of the different cardio-
vascular risk levels.
Patients with treated or untreated mild-to-moderate
essential hypertension were included in a multicentre,
prospective, non-comparative, open-label study. Patients
received lercanidipine (10 mg/day, uptitrated to 20 mg/
day) during 6 months.
A total of 3175 patients, age 63   10 years, 51% women,
were included. The cardiovascular risk was low in 237
patients, medium in 1396, high in 722, and very high in
820. At baseline, blood pressure (BP) was 159.5   11.7/
95.2   7.4 mmHg. BP was progressively higher according
to increase in cardiovascular risk. After 6 months of treat-
ment, BP was 136.0   9.7/79.7   6.8 mmHg. The
decrease in systolic BP and diastolic BP at each follow-up
visit compared with baseline was statistically signiﬁcant
both in the intergroup and intragroup comparisons
(p 0 0.001). Mean decreases of systolic blood pressure
(SBP) and diastolic blood pressure (DBP) were )18.5/
)13.8 mmHg in the low risk group, )23/)15.2 mmHg
in the medium risk group, )24.4/)16.1 mmHg in the
high risk group, and )27.4/)17.4 mmHg in the very high
risk group. Most frequent side effects were oedema (5.1%),
headache (3.3%), ﬂushes (2.5%), and asthenia (1%). Only
1.7% of patients discontinued antihypertensive medication
because of adverse events. Tolerability of lercanidipine was
independent of the cardiovascular risk group.
Lercanidipine was effective and well-tolerated in patients
with mild-to-moderate hypertension in the daily practice.
The effectiveness and safety of the drug were independent
of the degree of cardiovascular risk.
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INTRODUCTION
Cardiovascular disease is responsible for a large and increas-
ing proportion of death and disability worldwide. There is
evidence that cardiovascular mortality decrease observed in
industrialised countries in the second half of the 20th cen-
tury has occurred concomitantly with an improved control
of hypertension (1–3). However, 1 70% of hypertensive
patients have their blood pressure (BP) uncontrolled what
may result a signiﬁcant increase in cardiovascular risk (4,5).
Even small elevations above optimal BP values increase the
likelihood of developing hypertension and incurring target
organ damage (6,7). Therefore, BP lowering is critical to
help reduce the risk of cardiovascular disease and prevent
major coronary events. Nevertheless, although the control of
BP is important, clinical practice guidelines agree that the
aim of treatment in hypertensive patients should be not
only to control BP, but also protect the target organs affec-
ted by hypertension and reduce associated morbidity and
mortality (8,9). The latest European guidelines also empha-
sises that the global assessment of cardiovascular risk in the
hypertensive patient includes the identiﬁcation of lesions
caused by hypertension in the target organs. According to
the clinical guidelines, the cardiovascular risk is deﬁned by
the presence of cardiovascular risk factors, target organ dam-
age and associated clinical conditions (9).
Calcium channel blockers (CCB) clearly have a place
within the therapeutic tools aimed to reduce cardiovascular
risk. While earlier research were focused on increasing
potency and selectivity, the most recent developments have
brought dihydropyridinic CCB with a particularly slow
onset and long duration of action which may result a better
tolerability (10). Among them, lercanidipine is a third-
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through the blockade of the L-type calcium channels in cell
membranes (11–13). This drug has a high lipophilicity,
which enables a slower and smooth onset and longer dur-
ation of action than other DHP (14). In some studies, ler-
canidipine appears to be a well-tolerated drug with a low
adverse events rate because of its long-lasting and vascular-
selective calcium entry-blocking activity, while sympathetic
activation and reﬂex tachycardia is not induced (11,12).
The overall side effects rate is lower than observed with
other DHP (15,16). The efﬁcacy of lercanidipine has been
evaluated in non-comparative (17,18) and in comparative
studies with other CCB and different antihypertensive drugs
(19–23) showing a comparable effect with all of the cases.
The effect of lercanidipine has also been successfully evalu-
ated in severe or resistant hypertension, elderly subjects and
diabetics (23,24).
From a clinical point of view, it should be of interest to
know whether a BP-lowering drug is effective and well tol-
erated along the different cardiovascular risk proﬁles. This
would facilitate its use in overall hypertensive population in
daily practice. Thus, the LAURA study was aimed to assess
whether the effectiveness and tolerability of lercanidipine
may be different according to the cardiovascular risk level in
a wide sample of a hypertensive population.
PATIENTS AND METHODS
The LAURA study (estudio del comportamiento de LercA-
nidipino segUn niveles de riesgo cArdiovascular) was a
multicentre, prospective, observational, non-comparative,
open-label study, designed to determine the effectiveness
and safety of antihypertensive treatment with lercanidipine
in patients drawn from the general population, with differ-
ent cardiovascular risk proﬁles. The purpose of the study
was to evaluate the drug in conditions of daily clinical prac-
tice, to determine whether its effect was independent of the
cardiovascular risk level in a hypertensive population. The
study was conducted in the Spanish primary healthcare set-
ting in the summer time. A total of 500 family physicians
were invited to recruit patients with mild-to-moderate essen-
tial hypertension (eight patients each) who according to
their criteria were candidates to be treated with lercanidi-
pine. The expected study cohort included 4000 patients.
The duration of the study was 6 months.
Eligible patients were male and female aged   18 years
with newly diagnosed hypertension, deﬁned as systolic
blood pressure (SBP)   140 (  130 in diabetics) and
0 180 mmHg, and diastolic blood pressure (DBP)   90
(  80 in diabetics) and 0 110 mmHg, or previously trea-
ted hypertensives in whom the physician had decided to
switch the current therapy as a result of side effects or lack
of control were eligible. The exclusion criteria were severe
hypertension (SBP   180 mmHg or DBP   110 mmHg),
known hypersensitivity or history of severe adverse events to
any DHP, evidence of unstable angina or decompensated
congestive heart failure, myocardial infarction within the
previous 30 days, left ventricular outﬂow obstruction, liver
dysfunction (serum aminotransferases 1 2-fold increase or
serum bilirubin 1 1.5-fold increase above upper limit of
normal), and renal insufﬁciency [serum creatinine con-
centration 1 1.5 mg/dl (1 133 lmol/l) in men and
1 1.4 mg/dl (1 124 lmol/l) in women], as well as any
contraindication for prescribing lercanidipine as stated in
the technical form of the product. Pregnant women, nursing
mothers, or women of childbearing potential not using ade-
quate methods of contraception were also excluded.
Blood pressure readings were taken with a mercury
sphygmomanometer with the patient in a seated position
and the back supported, and after resting 5 min. The patients
were advised to avoid smoking or drinking coffee within
30 min before BP assessment. The visit BP was the average of
two separate measurements taken by the examining physician
(a third measure was obtained when there was a difference
  5 mmHg between the two readings). Adequate BP control
was deﬁned as SBP 0 140 mmHg and DBP 0 90 mmHg
(0 130 and 0 80 mmHg for diabetics) (9).
All patients underwent a complete physical examination
and investigation of other cardiovascular risk factors. With
the available information about BP levels, associated cardio-
vascular risk factors, target organ damage and associated
clinical conditions the patients were classiﬁed according to
the ESH/ESC guidelines 2003 in the different added car-
diovascular risk groups: low, medium, high or very high.
According to the ESH/ESC guidelines 2003 (9), the
following data were recorded: (a) cardiovascular risk fac-
tors: levels of SBP and DBP, age (men 1 55 years,
women 1 65 years), smoking, dyslipidaemia [total
cholesterol 1 250 mg/dl (1 6.5 mmol/l) or LDL-choles-
terol 1 155 mg/dl (1 4.0 mmol/l) or HDL-cholesterol
0 40 mg/dl (0 1.0 mmol/l) in men and 0 48 mg/dl
(0 1.2 mmol/l) in women], family history of premature
cardiovascular disease (at age 0 55 years in men and
0 65 years in women), abdominal obesity (abdominal cir-
cumference   102 cm in men and   88 cm in women)
and C-reactive protein   1 mg/dl; (b) target organ damage:
left ventricular hypertertrophy (electrocardiogram: Sokolow–
Lyons 1 38 mm; Cornell 1 2440 mm ms; echocardio-
gram: left ventricular mass index   125 in men and
  110 g/m
2 in women), ultrasound evidence of arterial wall
thickening (carotid IMT   0.9 mm) or atherosclerotic
plaque, slight increase in serum creatinine [1.3–1.5 mg/dl
(115–133 lmol/l) in men and 1.2–1.4 mg/dl (107–
124 lmol/l) in women], microalbuminuria [30–300 mg/
24 h; albumin–creatinine ratio   22 mg/g (  2.5 mg/
mmol) in men and   31 mg/g (  3.5 mg/mmol) in
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1 126 mg/dl (1 7.0 mmol/l) or postprandial plasma glu-
cose 1 198 mg/dl (1 11.0 mmol/l)]; (d) associated clinical
conditions: cerebrovascular disease (ischaemic stroke, cereb-
ral haemorrhage or transient ischaemic attack), heart disease
(myocardial infarction, angina, coronary revascularisation or
congestive heart failure), renal disease [diabetic nephropaty,
serum creatinine 1 1.5 mg/dl (1 133 lmol/l) in men and
1.4 mg/dl (124 lmol/l) in women or proteinuria
(1 300 mg/24 h)], peripheral vascular disease, advanced
retinopathy (haemorrhages or exudates, papilloedema).
The study medication was dispensed at the baseline visit.
The daily dose was one tablet of lercanidipine 10 mg, taken
in the morning, immediately after wake up. In previously
treated hypertensive patients, a washout period of 7–10 days
was required. Patients were followed at 4, 12, and 24 weeks
after beginning of treatment with lercanidipine. At each
visit, BP and heart rate were measured, treatment compli-
ance was checked, and patients were interviewed for the
occurrence of adverse events. Lercanidipine could be upti-
trated to 20 mg/day if BP control was not attained at any
visit. If BP was still uncontrolled after 20 mg other antihy-
pertensive medication could be added. The recommendation
of a reduced calorie diet and the prescription of hypocholes-
terolemic and hypoglycemic agents was left at the discretion
of the physician. All adverse events were designated by the
investigator as either drug or not drug-related. At the study
end, effectiveness and tolerability of treatment with lercanid-
ipine was assessed by the patients and the investigators as
‘poor’, ‘regular’, ‘good’ and ‘very good’. The study protocol
is shown in Table 1.
Statistical analysis
Categorical data are expressed as numbers and percentages
and continuous data as mean and standard deviation (SD).
The Student’s t-test for paired and unpaired data was used to
assess treatment effects on continuous variables. Categorical
variables were analysed with the chi-square (v
2) test. To study
differences in the quantitative variables over time as well as
progression, or between group differences, the analysis of vari-
ance (ANOVA) for repeated or independent measurements
was used. The analysis of covariance (ANCOVA) was used to
assess the effect of lercanidipine in subsets of the study popu-
lation divided according to low, medium, high and very high
cardiovascular risk groups. Statistical signiﬁcance was set at
p 0 0.05. The SPSS statistical software package for
Windows (version 9.1) was used to analyse the data.
RESULTS
A total of 3175 patients with a mean age of 63   10 years
were included in the study. 51% of patients were women.
Table 2 shows the baseline characteristics of the overall
study population. Remarkably, grade I hypertension was
diagnosed in 43% of patients and grade II in 57% and
baseline BP levels were SBP 159.5   11.7 mmHg and
DBP 95.2   7.4 mmHg. With regard to the cardiovascular
risk factors, the most frequent, after hypertension, was
hypercholesterolemia (32% of patients). The most prevalent
target organ damage was left ventricular hypertrophy (18%
of patients). Finally, the most prevalent associated clinical
conditions was ischaemic heart disease (10% of patients).
The patients were stratiﬁed as follows: 237 patients (7.5%)
at low cardiovascular risk, 1396 (44%) medium, 722
(22.7%) high, and 820 (25.8%) at very high risk.
Table 3 shows the previous drugs and reasons for the use
of lercanidipine. Treatment with lercanidipine was indicated
by the investigators because of poorly controlled hyperten-
sion with previous agents in 46% of patients, as ﬁrst therapy
in naı ¨ve hypertensives in 38%, and resulting from adverse
events related to antihypertensive drugs in 13%. Previous
antihypertensive medications are indicated in Table 3.
Changes in SBP and DBP during the study period in the
overall population as well as in the different cardiovascular
risk groups are shown in Table 4. At baseline, mean SBP
was 159.5   11.7 and DBP 95.2   7.4 mmHg. Baseline
BP was progressively higher in parallel with higher cardio-
vascular risk proﬁle. After 6 months of treatment, mean
SBP was 136.0   9.7 and DBP 79.7   6.8 mmHg. The
decrease in SBP and DBP at each follow-up visit compared
with baseline was statistically signiﬁcant both in the inter-
group and intragroup comparisons (p 0 0.001, one-way
ANOVA). The higher the cardiovascular risk level, the
greater the BP reductions. Mean decreases in SBP and DBP
were 18.5   3.3 and 13.8   2.3 mmHg in the low risk
group, 23   3.9 and 15.2   2.7 mmHg in the medium
risk group, 24.4   4.0 and 16.1   3.1 mmHg in the high
risk group, and 27.4   4.2 and 17.4   3.2 mmHg in the
Table 1 Flow chart of the study protocol
Procedure
Visit 0:
baseline
Visit 1:
4 weeks
Visit 2:
12 weeks
Visit 3:
24 weeks
SBP, DBP, heart rate X X X X
Eligibility criteria X
Bio-demographic data X
Anamnesis X
Physical examination X
Blood tests X X
Assessment of cardiovascular
risk
X
Study medication
(lercanidipine) supplied
XXX X
Adverse events X X X
Compliance with treatment X X X
SBP, systolic blood pressure; DBP, diastolic blood pressure.
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cardiovascular risk group at the follow-up compared with
baseline are shown in Figures 1 and 2. BP was controlled in
55% of patients treated with 10 mg/day of lercanidipine,
while systolic BP was controlled in 60.7% of patients, and
diastolic BP in 71.0%. In consequence, 45% of patients
were uptitrated to 20 mg/day of lercanidipine. After having
uptitrated to 20 mg/day of lercanidipine, BP was controlled
in 82% of patients, while systolic BP was controlled in
85.4% of patients, and diastolic BP in 89.1%. 18% of
patients needed to add other antihypertensive drugs to
achieve BP goal.
Ninety-four per cent of patients completed the 6-month
treatment period with lercanidipine. The incidence of
adverse events is shown in Table 5. As much as 11.5% of
patients presented adverse events, being the most frequent
the oedema (5.1%, more frequent with the 20 mg dose).
But only 1.7% of patients discontinued the medication
because of adverse events. No signiﬁcant differences in the
percent of patients suffering from adverse events according
to stratiﬁcation in the different risk groups were observed.
As much as 91% of physicians and 84% of patients consid-
ered that tolerability of antihypertensive treatment with
lercanidipine was ‘good’ or ‘very good’.
DISCUSSION
The present results obtained in a cohort of patients with
mild-to-moderate essential hypertension recruited in actual
conditions of daily clinical practice conﬁrm the effectiveness
and favourable tolerability proﬁle of lercanidipine. These
ﬁndings are consistent with data previously reported in
randomised trials (10,24) and in surveillance studies such as
the ELYPSE study (17).
Previous studies have shown that the majority of hyper-
tensive patients daily attended in Primary Care setting in
Spain belong to the medium or high coronary risk groups
(25,26). This point is relevant, because these patients are
normally polymedicated and they have an increased risk of
presenting side effects. The efﬁcacy of an antihypertensive
drugs does not only depend on BP control, but in its toler-
ability too. The presence of adverse events may be one of
the main causes for the poor patient compliance of the pre-
scribed therapy. Thus, the use of well tolerated drugs may
result in a better patient adherence and probably in a better
BP control (27–29). On the other hand, in usual care the
different antihypertensive drugs very rarely achieve BP con-
trol in 1 30–40% when used in monotherapy, and these
ﬁgures are much lower when considering BP control in high
coronary risk groups (25,26).
Table 3 Previous antihypertensive medication and reasons for the
use of lercanidipine
Data
Number of
patients Per cent
Total patients 3175 100
Naı ¨ve patients (newly treated) 1207 38
Previously treated with antihypertensive
drugs
1968 62
Previous antihypertensive medication
Diuretics 946 29.8
Angiotensin converting enzyme (ACE)
inhibitors
914 28.8
Beta-blockers 268 8.4
Calcium channel antagonists 213 6.7
Reasons to start treatment with lercanidipine
Poorly controlled blood pressure 1461 46
Adverse events 413 13
Other 94 3
Table 2 Characteristics of the study population at baseline
Baseline characteristics (n ¼ 3175)
Variables
Biodemographic data
Sex (male/female) M: 49
F: 51
Age (years), mean   SD 63   10
BMI (kg/m
2), mean   SD M: 28.2   3.8
F: 28.3   4.2
Waist circumference (cm), mean   SD M: 101.3   12.2
F: 96.8   14.1
Cardiovascular risk factors
Grade I hypertension
Grade II hypertension
43
57
Hypercholesterolemia 32
Current smoking 30
Family history cardiovascular disease 16
Diabetes mellitus 15
Target organ damage
Left ventricular hypertrophy 18
Atherosclerotic plaques 7
Mild renal impairment/microalbuminuria 5
Associated clinical conditions
Ischaemic heart disease 10
Peripheral arterial disease 6
Congestive heart failure 4
Renal failure 4
Cerebrovascular disease 3
Advanced retinopathy 1
Cardiovascular risk
Low risk 7.5
Medium risk 44
High 22.7
Very high 25.8
Clinical data
SBP (mmHg), mean   SD 159.5   11.7
DBP (mmHg), mean   SD 95.2   7.4
Heart rate (bpm), mean   SD 68.4   4.2
M, male; F, female; BMI, body mass index; SBP, systolic blood pressure;
DPB, diastolic blood pressure.
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pertensive effectiveness among the different degrees of car-
diovascular risk. In fact, lercanidipine showed to be more
effective in patients with higher cardiovascular risk levels,
most likely to be in relation to higher SBP and DBP val-
ues at baseline. Mean decreases of SBP and DPB were
Table 4 Changes of SBP and DBP during the study period
Blood pressure, mean   SD All patients, n ¼ 3175
Cardiovascular disease risk groups
Low, n ¼ 237 Medium, n ¼ 1396 High, n ¼ 722 Very high, n ¼ 820
Visit 0 (baseline)
SBP, mmHg 159.5   11.7 149.5   5.4 158.3   9.7 159.7   10.9 164.2   14.5
DBP, mmHg 95.2   7.4 92.0   4.8 94.8   6.7 95.3   7.3 96.7   8.6
Visit 1 (4 weeks)
SBP, mmHg 144.9   11.5 136.8   7.7 144.4   10.5 145.5   11.5 147.9   12.8
DBP, mmHg 85.6   7.5 82.9   6.1 85.6   7.2 85.8   7.6 86.3   8.1
Visit 2 (12 weeks)
SBP, mmHg 138.9   10.1 133.4   6.7 138.5   9.4 139.3   10.1 140.9   11.5
DBP, mmHg 81.9   6.9 80.3   6.4 81.9   6.6 81.9   6.8 82.3   7.8
Visit 3 (24 weeks)
SBP, mmHg 136.0   9.7 130.7   6.9 135.9   9.1 136.1   8.7 137.5   11.3
DBP, mmHg 79.7   6.8 78.3   6.8 79.7   6.5 79.8   6.3 79.8   7.5
SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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)27.4/)17.4 mmHg in the very high risk group. Moreover,
the majority of patients were controlled only with lercanidi-
pine (18% of patients needed to add another antihyperten-
sive drug to achieve a good BP control) including high risk
group. In this large study, the efﬁcacy of this drug has
therefore proven to be similar to the previously published
papers (17–23).
On the other hand, although the BP lowering effect of
lercanidipine was greater in patients with higher cardiovas-
cular risk levels, tolerability of the drug was independent of
the cardiovascular risk proﬁle. Therefore, lercanidipine was
found to be an effective and well-tolerated antihypertensive
drug for any hypertensive patient in daily clinical practice,
regardless the cardiovascular risk proﬁle. This represents an
added value at the time of prescribing this antihypertensive
medication in all kind of hypertensive patients, from low to
high coronary risk. This good tolerability proﬁle implies a
low withdrawal rate, indicating a satisfactory patient
compliance.
Lercanidipine appears to be associated with a better toler-
ability proﬁle and less risk of vasodilation-related adverse
reactions compared with other DHPs in the clinical practice
setting (15,16,19–21). However, the percentage of patients
with oedema was superior in our patients compared with
others treated with lercanidipine, probably because our
study was performed in the summer time. As it is known,
the presence of oedema is more frequent during this season
because of a bigger trend to the vasodilatation.
In conclusion, despite the limitations that this kind of
observational intervention studies which are open and non-
comparative, the LAURA study demonstrates that Lercanid-
ipine is an a effective and well-tolerated antihypertensive
agent in daily clinical practice, regardless the cardiovascular
risk proﬁle. These results conﬁrm the previous ﬁndings
from randomised controlled trials, and support that this
drug is a fair option to be considered in the antihyperten-
sive armamentarium.
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